Nasal vaccination with P6 outer membrane protein and α-galactosylceramide induces nontypeable Haemophilus influenzae-specific protective immunity associated with NKT cell activation and dendritic cell expansion in nasopharynx

Vaccine

Volumn 28, Issue 31, 2010, Pages 5068-5074

  Noda, Kenji ^a   Kodama, Satoru ^a   Umemoto, Shingo ^a   Abe, Nobuyuki ^a   Hirano, Takashi ^a   Suzuki, Masashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

GalCer; Dendritic cell; Nasal vaccine; NKT cell; NTHi

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ADJUVANT; ALPHA GALACTOSYLCERAMIDE; COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON; HAEMOPHILUS INFLUENZAE VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; OUTER MEMBRANE PROTEIN; ALPHA-GALACTOSYLCERAMIDE; BACTERIUM ANTIBODY; GALACTOSYLCERAMIDE; HAEMOPHILUS VACCINE; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; P6 OUTER MEMBRANE PROTEIN, HAEMOPHILUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HAEMOPHILUS INFLUENZAE; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; IMMUNOHISTOCHEMISTRY; MOUSE; NASOPHARYNX; NATURAL KILLER CELL; NONHUMAN; NOSE MUCOSA; OTITIS MEDIA; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; BLOOD; HAEMOPHILUS INFECTIONS; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MUCOSAL IMMUNITY; NATURAL KILLER T CELL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BACTERIAL OUTER MEMBRANE PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; GALACTOSYLCERAMIDES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NASOPHARYNX; NATURAL KILLER T-CELLS;

EID: 77954758686     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.05.005     Document Type: Article

References (41)

1. Murphy T.F. Respiratory infections caused by non-typeable Haemophilus influenzae. Curr Opin Infect Dis 2003, 16(2):129-134.
2. Poolman J.T., Bakaletz L., Cripps A., Denoel P.A., Forsgren A., Kyd J., et al. Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. Vaccine 2000, 19(Suppl. 1):S108-S115.
3. Czerkinsky C., Anjere F., McGhee J.R., George-Chandy S., Holmgren J., Kieny M.P., et al. Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev 1999, 170:197-222.
4. Belyakov I.M., Derby M.A., Ahlers J.D., Kelsall B.L., Earl P., Moss B., et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci U S A 1998, 95(4):1709-1714.
5. Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001, 1(3):209-219.
6. Kozlowski P.A., Neutra M.R. The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med 2003, 3(3):217-228.
7. Kiyono H., Fukuyama S. NALT versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004, 4(9):699-710.
8. Holmgren J., Czerkinsk C. Mucosal immunity and vaccines. Nat Med 2005, 11(Suppl. 4):S45-S53.
9. Holmgren J., Czerkinsky C., Eriksson K., Mharandi A. Mucosal immunization and adjuvant: a brief overview of recent advances and challenges. Vaccine 2003, 21(Suppl. 2):S89-S95.
10. Kodama S., Suenaga S., Hirano T., Suzuki M., Mogi G. Induction of specific immunoglobulin A and Th2 immune responses to P6 outer membrane protein of nontypeable Haemophilus influenzae in middle ear mucosa by intranasal immunization. Infect Immun 2000, 68(4):2294-2300.
11. Sabirov A., Kodama S., Hirano T., Suzuki M., Mogi G. Intranasal immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alfa production in the murine model of otitis media. Infect Immun 2001, 69(5):2964-2971.
12. van Ginkel F.W., Jacson R.J., Yuki Y., McGhee J.R. The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000, 165(9):4778-4782.
13. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997, 278(5343):1626-1629.
14. Taniguchi M., Seino K., Nakayama T. NKT cell system: bridging innate and acquired immunity. Nat Immunol 2003, 4(12):1164-1165.
15. Fujii S., Shimizu K., Smith C., Boifaz L., Steinman R.M. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003, 198(2):267-279.
16. Chung Y., Chang W.S., Kim S., Kang C.Y. NKT cell ligand α-galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation. Eur J Immunol 2004, 34(9):2471-2479.
17. Ko S.Y., Ko H.J., Chang W.S., Park S.H., Kweon M.N., Kang C.Y. α-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 2005, 175(5):3309-3317.
18. Kodama S., Hirano T., Noda K., Abe N., Suzuki M. A single nasal dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal application, enhances nontypeable Haemophilus influenzae-specific long term mucosal immune responses in the nasopharynx. Vaccine 2010, 28(13):2510-2516.
19. Abe N., Kodama S., Hirano T., Eto M., Suzuki M. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against nontypeable Haemophilus influenzae in the nasopharynx. Laryngoscope 2006, 116(3):407-412.
20. Bertot G.M., Becker P.D., Guzman C.A., Grinstein S. Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae. J Infect Dis 2004, 189(7):1304-1312.
21. Cerundolo V., Silk J.D., Masri S.H., Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009, 9(1):28-38.
22. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of Vα 14 NKT cells by glycosylceramides. Science 1997, 278:1626-1629.
23. Spada F.M., Koezuka Y., Porcelli S.A. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 1998, 188(8):1529-1534.
24. Vincent M.S., Leslie D.S., Gumperz J.E., Xiong X., Grant E.P., Brenner M.B. CD1-dependent dendritic cell instruction. Nat Immunol 2002, 3(12):1163-1168.
25. Fujii S., Lui K., Smith C., Bonito A.J., Steinman R.M. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004, 199(2):1607-1618.
26. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003, 171(10):5140-5147.
27. Kamijuku H., Nagata Y., Jiang X., Ichinohe T., Tashiro T., Mori K., et al. Mechanism of NKT cell activation by coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol 2008, 1(3):208-218.
28. Silk J.D., Salio M., Reddy B.G., Shepherd D., Gileadi U., Brown J., et al. Non-glycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J Immunol 2008, 180(10):6452-6456.
29. Hermans I.F., Silk J.D., Gileadi U., Masri S.H., Shepherd D., Farrand K.J., et al. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J Imunol 2007, 178(5):2721-2729.
30. Galli G., Nuti S., Tavarini S., Galli-Stampino L., De Lalla C., Casorati G., et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med 2003, 197(8):1051-1057.
31. Galli G., Pittoni P., Tonti E., Malzone C., Uematsu Y., Tortoli M., et al. Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A 2007, 104(10):3984-3989.
32. Barral P., Eckl-Dorna J., Harwood N.E., De Santo C., Salio M., Illarionov P., et al. B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo. Proc Natl Acad Sci U S A 2008, 105(24):8345-8350.
33. Leadbetter E.A., Brigl M., Illarionov P., Cohen N., Luteran M.C., Pillai S., et al. NKT cells provide lipid antigen-specific cognate help for B cells. Proc Natl Acad Sci U S A 2008, 105(24):8339-8344.
34. Finkelman F.D., Holmes J., Katona I.M., Urban J.F., Beckmann M.P., Park L.S., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990, 8:303-333.
35. Beagley K.W., Eldridge J.H., Kiyono H., Everson M.P., Koopman W.J., Honjo T., et al. Recombinant murine IL-5 induces high rate IgA synthesis in cycling IgA-positive Peyer's patch B cells. J Immunol 1988, 141(6):2035-2042.
36. Beagley K.W., Eldridge J.H., Lee H., Kiyono H., Everson M.P., Koopman W.J., et al. Interleukins and IgA synthesis. Human and murine interleukin 6 induce high-rate IgA secretion in IgA-committed B cells. J Exp Med 1989, 169(6):2133-2148.
37. Defrance T., Vanbervliet B., Briere F., Durand I., Rousset F., Banchereau J. Interleukin 10 and transforming growth factor B cooperate to induce anti-CD40-activated native human B cells to secrete immunoglobulin A. J Exp Med 1992, 175(3):671-682.
38. Aicher W.K., Fujiashi K., Yamamoto M., Kiyono H., McGhee J.R. Effect of the lpr/lpr mutation of T and B cell populations in the lamina propria of small intestine, a mucosal effector site. Int Immunol 1992, 4(9):959-968.
39. Hiroi T., Fujihashi K., McGhee J.R., Kiyono H. Polarized Th2 cytokine expression by both mucosal γδ and αβ T cells. Eur J Immunol 1995, 25(10):2743-2751.
40. +NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004, 103(2):383-389.
41. Giaccone G., Punt C.J., Ando Y., Ruijter R., Nishi N., Peters M., et al. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002, 8(12):3702-3709.